Clinical trial
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
NCT02419495 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- June 26, 2015
- Completion date
- September 16, 2024
- Enrollment
- 221 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant solid neoplasm, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, fallopian tube carcinoma, metastatic lung non-small cell carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, metastatic renal cell carcinoma, ovarian carcinoma, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, primary peritoneal carcinoma, stage iii lung cancer ajcc v8, stage iii renal cell cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv lung cancer ajcc v8, stage iv renal cell cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8, triple-negative breast carcinoma, unresectable lung non-small cell carcinoma, unresectable melanoma, unresectable renal cell carcinoma